| Thu 26 Jun 2008, 11:48 | | APN - Aspen Pharmacare Holdings - Anti-Retroviral Tender Results |
|
APN
APN
APN - Aspen Pharmacare Holdings - Anti-Retroviral Tender Results
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
("Aspen" or "the Company")
PRESS RELEASE
ANTI-RETROVIRAL TENDER RESULTS
Following the announcement of the Anti-Retroviral (ARV) Tender results by the
Department of Health earlier today, Aspen Pharmacare Holdings Limited is pleased
to announce that its South African operating company (Aspen) has been successful
in winning a significant portion of the tender, in spite of strong competition.
The tender is effective for a period of two years, commencing retrospectively
from 01 June 2008.
In addition to maintaining the supply contract for existing tender items, Aspen
has also secured volumes for two new products, Aspen Efavirenz and Tenofivir.
Tenofivir is a key new molecule to the ARV tender. Increased usage is
anticipated over the tender period. Aspen secured more than 50% by volume of
the entire ARV tender based upon expected future demand as published in the
invitation to tender.
Aspen`s share of the ARV Tender award included the following:
Product Percentage won
Efavirenz 600mg tablets 30%
Stavudine 15mg tablets 100%
Stavudine 20mg tablets 100%
Stavudine 30mg tablets 80%
Zidovudine 300mg tablets 60`s 100%
Zidovudine 100mg capsules 100`s 100%
Zidovudine 200ml syrup 100%
Zidovudine 20ml syrup 100%
Lamivudine 240ml syrup 100%
Lamivudine 150mg tablets 80%
Nevirapine tablets 100%
Nevirapine suspension 100%
Lamzid tablets 100%
Tenofivir tablets 100%
The South African ARV Tender is the largest of its kind in the world. Since
inception, Aspen has been the major supplier to this programme. With the growing
number of HIV/AIDS patients under treatment, the actual volumes supplied to the
State during the last tender has continued to show incremental growth each
month. Aspen has been able to respond to this growth in demand. Aspen produces
the ARV products at its South African facilities, based in Port Elizabeth.
Recent investments have been made in extending manufacturing capability and
upgrading existing facilities. This has resulted in unlocking capacity and
ensuring that demand requirements are met.
The positive tender results confirm Aspen`s position as a competitive, reliable
and valued supplier to the State. In his response to the ARV Tender results,
Aspen Group Chief Executive, Stephen Saad said: "The results reflect positively
on our competitiveness, breadth of our product offering and on the effectiveness
of our service delivery. Aspen has its roots firmly in South African soil and is
proud to be a leading contributor to healthcare in South Africa."
26 June 2008
Sponsor:
Investec Bank Limited
Date: 26/06/2008 11:48:15 Produced by the JSE SENS Department.
The SENS service is an information dissemination service administered by the
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or
implicitly, represent, warrant or in any way guarantee the truth, accuracy or
completeness of the information published on SENS. The JSE, their officers,
employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature,
howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
